Public signal · 1-minute delayed

Signal brief

Source-backed market context you can read and share without an account.

Browse signals

MESOVery BullishFDA Approvalnews

High materiality9/10

Mesoblast's Cell Therapy Treatment For Graft Versus Host Disease Gets FDA Approval, Stock Surges

Dec 19, 2024, 7:01 AM EST1 sourcesAI-analyzed

Why it may matterVerify against the original reporting

The FDA approval is a significant catalyst, similar to past approvals boosting biotech stocks.

AI summary

What happened, with direct paths to the underlying reporting

FDA approved MESO's Ryoncil as the first MSC therapy in the U.S. Ryoncil treats steroid-refractory acute graft vs host disease in children. Approximately 10,000 patients in the U.S. undergo allogeneic transplants annually. Phase 3 trial showed 70% overall response rate for Ryoncil within 28 days. MESO stock rose 42.60% to $17.47 after the announcement.

FDA approved MESO's Ryoncil as the first MSC therapy in the U.S.
Ryoncil treats steroid-refractory acute graft vs host disease in children.
Approximately 10,000 patients in the U.S. undergo allogeneic transplants annually.
Phase 3 trial showed 70% overall response rate for Ryoncil within 28 days.
MESO stock rose 42.60% to $17.47 after the announcement.

How to read this signal

Transparent limits for an AI-generated research aid

StockNews.AI groups source reporting, classifies the event, and measures subsequent price movement. This is informational research, not investment advice. Prices may be delayed or unavailable.

Mesoblast's Cell Therapy Treatment For Graft Versus Host Disease Gets FDA Approval, Stock Surges

Mesoblast completes Phase 3 CLBP treatment; readout expected in 2027

Mesoblast Touts High Survival Rates For FDA-Approved Cell Therapy

MESO Stock Up as FDA Approves Ryoncil for Graft Versus Host Disease

US FDA approves Mesoblast's cell therapy for graft-versus-host disease